Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at several upcoming investor conferences. Key events include the Cowen 41st Annual Health Care Conference on March 4, 2021, the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. A replay of the H.C. Wainwright presentation and a live webcast of the Oppenheimer presentation will be available on their website. Milestone focuses on developing etripamil for cardiovascular treatment.
Milestone Pharmaceuticals (Nasdaq: MIST) has announced that its President and CEO, Joseph Oliveto, will present at two upcoming investor conferences. The events include the Piper Sandler 32nd Virtual Annual Healthcare Conference and the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 4:20 p.m. ET. A replay of the Piper Sandler fireside chat is available on the company's website, along with a live webcast of the Evercore presentation. Milestone is focused on developing etripamil for cardiovascular treatments.
Milestone Pharmaceuticals announced the enrollment of the first patient in the RAPID Phase 3 trial for etripamil, a treatment for paroxysmal supraventricular tachycardia (PSVT). The trial aims to assess the efficacy of a second dose of etripamil in patients who do not achieve symptom relief within 10 minutes. With a target of 500 patients and 180 confirmed SVT events, the data is expected by late 2021/early 2022. This trial follows the NODE-301 trial, which showed promising safety and efficacy results. Success in RAPID could support future FDA approvals for etripamil.
Milestone Pharmaceuticals (Nasdaq: MIST) reported its Q3 2020 financial results, highlighting plans to reopen enrollment in the pivotal Phase 3 RAPID trial for etripamil by year-end. The company raised $51.7 million through a public offering, reinforcing its financial position with $102.9 million in cash and equivalents. Q3 research and development expenses decreased to $8.2 million from $9.5 million last year, while general and administrative costs rose to $3.0 million. The company's operating loss narrowed to $12.1 million compared to $13.7 million in Q3 2019.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 7:55 AM ET. The event will be held online, allowing broader access. A live webcast of the presentation can be viewed on Milestone's website, with a replay available for 30 days post-event. Milestone focuses on developing innovative cardiovascular treatments, particularly etripamil, currently in Phase 3 clinical trials.
Milestone Pharmaceuticals (Nasdaq: MIST) has priced a public offering of 3,810,097 common shares at $5.25 each, alongside pre-funded warrants to purchase 4,761,903 shares at $5.24 each. The offering aims to raise gross proceeds of $45 million to fund clinical development of etripamil and for general corporate purposes. The offering is set to close on October 27, 2020, pending customary closing conditions. Underwriters, Jefferies and Piper Sandler, also have a 30-day option to purchase an additional 1,285,800 shares.
Milestone Pharmaceuticals (Nasdaq: MIST) announced a proposed public offering of common shares and pre-funded warrants to certain investors. The offering, managed by Jefferies and Piper Sandler, is subject to market conditions. Milestone plans to use the net proceeds primarily for the clinical development of etripamil, its lead candidate for cardiovascular treatment, alongside capital expenditures and general corporate purposes. The underwriters will have a 30-day option to purchase an additional 15% of the offering. Details will be available in a prospectus supplement filed with the SEC.
Milestone Pharmaceuticals (Nasdaq: MIST) announced that Joseph Oliveto, President and CEO, will present at two key investor conferences. The first is the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15, 2020, at 11:30 a.m. ET. The second is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020, at 2:30 p.m. ET. Live webcasts of the presentations will be available on Milestone's website, with archived replays accessible for 30 days post-event.
Milestone Pharmaceuticals (MIST) reported Q2 2020 financial results, noting a cash position of $85.4 million and an operating loss of $13.1 million, improving from a $14.3 million loss in Q2 2019. The company is set to reopen its RAPID study for etripamil in treating paroxysmal supraventricular tachycardia (PSVT) later this year, following FDA guidance. A $25 million private placement was recently completed to fund ongoing clinical trials. R&D expenses for Q2 2020 decreased to $8.6 million from $10.5 million year-over-year.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 1:00 PM ET. The event will take place virtually, and a live webcast will be available on Milestone's website. An archived replay will also be accessible for 30 days post-presentation. Milestone focuses on developing cardiovascular medicines and operates in both Canada and the U.S. For more details, visit www.milestonepharma.com.